Click here to get full coverage on $CRSP stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

$CRSP stock is down 3% today. Here's what we see in our data.  Quiver Quantitative

$CRSP stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025  MarketBeat

CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts - ts2.tech

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts  ts2.tech

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts - ts2.tech

Click here to get full coverage on CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies - Yahoo Finance

CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies  Yahoo Finance

CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies - Yahoo Finance

Click here to get full coverage on Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation - Nasdaq

Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation  Nasdaq

Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation - Nasdaq

Click here to get full coverage on Is CRSP a good long term investment - Market Liquidity Analysis & Free Triple Digit Wealth Increase - earlytimes.in

Is CRSP a good long term investment - Market Liquidity Analysis & Free Triple Digit Wealth Increase  earlytimes.in

Is CRSP a good long term investment - Market Liquidity Analysis & Free Triple Digit Wealth Increase - earlytimes.in

Click here to get full coverage on Morningstar Plans to Acquire CRSP, Solidifying Position as a Top-Tier Global Index Provider - Morningstar

Morningstar Plans to Acquire CRSP, Solidifying Position as a Top-Tier Global Index Provider  Morningstar

Morningstar Plans to Acquire CRSP, Solidifying Position as a Top-Tier Global Index Provider - Morningstar

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know - MSN

CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know  MSN

CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know - MSN

Click here to get full coverage on How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors - Yahoo Finance

How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors  Yahoo Finance

How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors  ts2.tech

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech

Click here to get full coverage on What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors - Yahoo Finance

What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors  Yahoo Finance

What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics (CRSP): Revisiting Valuation After Recent Share Price Pullback - Yahoo Finance

CRISPR Therapeutics (CRSP): Revisiting Valuation After Recent Share Price Pullback  Yahoo Finance

CRISPR Therapeutics (CRSP): Revisiting Valuation After Recent Share Price Pullback - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility - Yahoo Finance

CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility  Yahoo Finance

CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics (CRSP): Exploring Valuation After Recent 25% Share Price Decline - Yahoo Finance

CRISPR Therapeutics (CRSP): Exploring Valuation After Recent 25% Share Price Decline  Yahoo Finance

CRISPR Therapeutics (CRSP): Exploring Valuation After Recent 25% Share Price Decline - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance

Click here to get full coverage on Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? - Yahoo Finance

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?  Yahoo Finance

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? - Yahoo Finance

Click here to get full coverage on Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - Yahoo Finance

Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance  Yahoo Finance

Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration - simplywall.st

CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration  simplywall.st

CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration - simplywall.st

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? - Yahoo Finance

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?  Yahoo Finance

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know - Yahoo Finance

Click here to get full coverage on 3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term  The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool

Click here to get full coverage on RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform - Yahoo Finance

RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform  Yahoo Finance

RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know  Yahoo Finance

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Click here to get full coverage on COP27 Climate Responses for Sustaining Peace Initiative - Welcome to the United Nations

COP27 Climate Responses for Sustaining Peace Initiative  Welcome to the United Nations

COP27 Climate Responses for Sustaining Peace Initiative - Welcome to the United Nations

Click here to get full coverage on Chair of UChicago-Owned Financial Research Center Defends $375 Million Sale, Says It Was Unrelated to University Financial Issues - Chicago Maroon

Chair of UChicago-Owned Financial Research Center Defends $375 Million Sale, Says It Was Unrelated to University Financial Issues  Chicago Maroon

Chair of UChicago-Owned Financial Research Center Defends $375 Million Sale, Says It Was Unrelated to University Financial Issues - Chicago Maroon

Click here to get full coverage on Watch Paul Lohrey of CRSP discuss the Evolution of Market Indexes and Financial Inclusion - ETFGI

Watch Paul Lohrey of CRSP discuss the Evolution of Market Indexes and Financial Inclusion  ETFGI

Watch Paul Lohrey of CRSP discuss the Evolution of Market Indexes and Financial Inclusion - ETFGI

Click here to get full coverage on Morningstar to Acquire Index Provider CRSP - plansponsor

Morningstar to Acquire Index Provider CRSP  plansponsor

Morningstar to Acquire Index Provider CRSP - plansponsor

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Click here to get full coverage on Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? - Zacks Investment Research

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?  Zacks Investment Research

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? - Zacks Investment Research

Click here to get full coverage on When index funds mix but don’t match - corporate.vanguard.com

When index funds mix but don’t match  corporate.vanguard.com

When index funds mix but don’t match - corporate.vanguard.com

Click here to get full coverage on Is CRISPR (CRSP) Using CTX310 To Quietly Redefine Its Rare-Disease-Centric Investment Story? - Yahoo Finance

Is CRISPR (CRSP) Using CTX310 To Quietly Redefine Its Rare-Disease-Centric Investment Story?  Yahoo Finance

Is CRISPR (CRSP) Using CTX310 To Quietly Redefine Its Rare-Disease-Centric Investment Story? - Yahoo Finance

Click here to get full coverage on Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - Yahoo Finance

Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?  Yahoo Finance

Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - Yahoo Finance

Click here to get full coverage on Can Renewed Analyst Optimism on CRISPR Therapeutics (CRSP) Earnings Reshape Its Long-Term Growth Narrative? - Yahoo Finance

Can Renewed Analyst Optimism on CRISPR Therapeutics (CRSP) Earnings Reshape Its Long-Term Growth Narrative?  Yahoo Finance

Can Renewed Analyst Optimism on CRISPR Therapeutics (CRSP) Earnings Reshape Its Long-Term Growth Narrative? - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Click here to get full coverage on KCC’s Future Scientists Take the Spotlight at the 2025 CRSP Symposium - The City University of New York

KCC’s Future Scientists Take the Spotlight at the 2025 CRSP Symposium  The City University of New York

KCC’s Future Scientists Take the Spotlight at the 2025 CRSP Symposium - The City University of New York

Click here to get full coverage on CRSP Maintains Market Outperform Rating: Latest Analyst Insights | CRSP Stock News - GuruFocus

CRSP Maintains Market Outperform Rating: Latest Analyst Insights | CRSP Stock News  GuruFocus

CRSP Maintains Market Outperform Rating: Latest Analyst Insights | CRSP Stock News - GuruFocus

Click here to get full coverage on Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? - The Motley Fool

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026?  The Motley Fool

Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? - The Motley Fool

Click here to get full coverage on Morningstar to Acquire CRSP from University of Chicago for $375M - Built In Chicago

Morningstar to Acquire CRSP from University of Chicago for $375M  Built In Chicago

Morningstar to Acquire CRSP from University of Chicago for $375M - Built In Chicago

Click here to get full coverage on Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? - Yahoo Finance

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?  Yahoo Finance

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? - Yahoo Finance

Click here to get full coverage on 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) - The Motley Fool

1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)  The Motley Fool

1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) - The Motley Fool

Click here to get full coverage on Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP) - Yahoo Finance

Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP)  Yahoo Finance

Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP) - Yahoo Finance

Click here to get full coverage on What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance

What Makes Crispr Therapeutics Ag (CRSP) a Good Buy?  Yahoo Finance

What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP) - Seeking Alpha

CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP)  Seeking Alpha

CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP) - Seeking Alpha

Click here to get full coverage on CRISPR Therapeutics (CRSP): Revisiting Valuation in Light of New Clinical Data and Expanding Commercial Momentum - Yahoo Finance

CRISPR Therapeutics (CRSP): Revisiting Valuation in Light of New Clinical Data and Expanding Commercial Momentum  Yahoo Finance

CRISPR Therapeutics (CRSP): Revisiting Valuation in Light of New Clinical Data and Expanding Commercial Momentum - Yahoo Finance

Click here to get full coverage on Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock  Yahoo Finance

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates  Yahoo Finance

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Crispr Therapeutics gains amid takeover speculation (CRSP:NASDAQ) - Seeking Alpha

Crispr Therapeutics gains amid takeover speculation (CRSP:NASDAQ)  Seeking Alpha

Crispr Therapeutics gains amid takeover speculation (CRSP:NASDAQ) - Seeking Alpha

Click here to get full coverage on A Look at CRISPR Therapeutics’s (CRSP) Valuation Following First Public SyNTase Gene Editing Data Reveal - Yahoo Finance

A Look at CRISPR Therapeutics’s (CRSP) Valuation Following First Public SyNTase Gene Editing Data Reveal  Yahoo Finance

A Look at CRISPR Therapeutics’s (CRSP) Valuation Following First Public SyNTase Gene Editing Data Reveal - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC - MarketBeat

CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC  MarketBeat

CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC - MarketBeat

Click here to get full coverage on CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - Yahoo Finance

CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading  Yahoo Finance

CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - Yahoo Finance

Click here to get full coverage on 2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool

2 Stocks That Could Soar by 52% and 282%, According to Wall Street  The Motley Fool

2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool

Click here to get full coverage on University of Chicago selling Center for Research in Security Prices to Morningstar - CBS News

University of Chicago selling Center for Research in Security Prices to Morningstar  CBS News

University of Chicago selling Center for Research in Security Prices to Morningstar - CBS News

Click here to get full coverage on CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains - Sahm

CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains  Sahm

CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains - Sahm

Click here to get full coverage on BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration - Yahoo Finance

BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration  Yahoo Finance

BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration - Yahoo Finance

Click here to get full coverage on Trend Review: Can CRSP stock deliver strong Q4 earnings - Day Trade & Safe Capital Growth Plans - moha.gov.vn

Trend Review: Can CRSP stock deliver strong Q4 earnings - Day Trade & Safe Capital Growth Plans  moha.gov.vn

Trend Review: Can CRSP stock deliver strong Q4 earnings - Day Trade & Safe Capital Growth Plans - moha.gov.vn

Click here to get full coverage on CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates - Zacks Investment Research

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates  Zacks Investment Research

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates - Zacks Investment Research

Click here to get full coverage on CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?  Yahoo Finance

CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Click here to get full coverage on CRISPR Therapeutics Stock (CRSP) Opinions on CTX310 Phase 1 Data Release | CRSP Stock News - Quiver Quantitative

CRISPR Therapeutics Stock (CRSP) Opinions on CTX310 Phase 1 Data Release | CRSP Stock News  Quiver Quantitative

CRISPR Therapeutics Stock (CRSP) Opinions on CTX310 Phase 1 Data Release | CRSP Stock News - Quiver Quantitative

Click here to get full coverage on Needham Maintains CRISPR Therapeutics (CRSP) Buy Recommendation - Nasdaq

Needham Maintains CRISPR Therapeutics (CRSP) Buy Recommendation  Nasdaq

Needham Maintains CRISPR Therapeutics (CRSP) Buy Recommendation - Nasdaq

Click here to get full coverage on $CRSP stock is down 5% today. Here's what we see in our data. - Quiver Quantitative

$CRSP stock is down 5% today. Here's what we see in our data.  Quiver Quantitative

$CRSP stock is down 5% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? - Yahoo Finance

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?  Yahoo Finance

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? - Yahoo Finance

Click here to get full coverage on $CRSP stock is down 4% today. Here's what we see in our data. - Quiver Quantitative

$CRSP stock is down 4% today. Here's what we see in our data.  Quiver Quantitative

$CRSP stock is down 4% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on CRSP: Needham Reiterates Buy Rating with Stable Price Target | C - GuruFocus

CRSP: Needham Reiterates Buy Rating with Stable Price Target | C  GuruFocus

CRSP: Needham Reiterates Buy Rating with Stable Price Target | C - GuruFocus

Click here to get full coverage on What CRISPR Therapeutics (CRSP)'s Positive CTX460 Gene Editing Data Means for Shareholders - Yahoo Finance

What CRISPR Therapeutics (CRSP)'s Positive CTX460 Gene Editing Data Means for Shareholders  Yahoo Finance

CRSP

Price Chart

Key Statistics

Technicals

About CRSP

Latest News

$CRSP stock is down 3% today. Here's what we see in our data. - Quiver Quantitative

CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts - ts2.tech

Advanced Charts

Top Gainers

Top Losers